Articles tagged with Cancer Medication
A phase III clinical trial shows tucatinib significantly improves survival rates in women with HER2+ breast cancer, especially those with brain metastases. The study found nearly tripled one-year progression-free survival and doubled two-year overall survivor compared to standard treatment.
A new approach to treating MLL-rearranged leukaemia (MLL-r leukaemias) has shown promising results, with a small molecule inhibitor called VTP50469 producing a 'dramatic response' in specially-bred mice. The therapy is designed to target molecules critical for the survival and growth of cancer cells.
Researchers at Hollings Cancer Center discovered that combining a polo-like kinase 1 inhibitor with a standard chemotherapeutic agent reduced TNBC tumor volume four times more effectively than the agent alone. The combination also reduces cancer stem cells, associated with metastasis.
A study found that more than 25% of lung cancer patients are prescribed medications with potential cardiac risk, and almost 10% take multiple such medications. The researchers argue that these criteria may be excessive and could be too strict, excluding patients who don't pose a cardiac risk.
Researchers at UCLA Jonsson Comprehensive Cancer Center found that inhibiting PAK4 gene overcomes resistance to anti-PD-1 therapy in preclinical models. Biopsies from patients with melanoma showed high expression of PAK4, correlating with suppressed immune cell infiltration into tumors.
A new book published by international cancer experts offers promising research findings on Latino cancer and strategies for reducing health disparities. The book provides recommendations for creating studies based on subgroups and moving towards precision medicine to address the projected 142% rise in Latino cancer cases by 2030.
A recent study found that a combination of chemotherapy and immunotherapy caused serious side effects in 32% of older patients enrolled on a leukemia trial. The findings highlight the need for caution when enrolling vulnerable populations in clinical trials.
A new clinical trial has found that patients with limited-stage, aggressive non-Hodgkin's lymphoma who have a clear PET scan can skip radiation therapy and still achieve excellent results. The study showed that 91% of patients who received no radiation were alive five years after treatment.
A study by Dana-Farber researchers suggests that adding venetoclax to a reduced-intensity drug regimen prior to stem cell transplant can increase the chances of transplant success. The treatment has been found to be safe and does not impair donor cells' ability to engraft in recipients.
Researchers at UT Health San Antonio have discovered a new class of drugs called PROTACs that target the BCL-XL protein in cancer cells. These drugs show safe and potent antitumor activity, potentially treating T-cell malignancies such as leukemia and lymphoma.
A simple health questionnaire could be a highly effective tool to pre-screen people for early signs of oesophageal cancer, enabling much earlier diagnosis and treatment. Eight factors were identified as markers in those individuals who had Barrett's oesophagus or went on to develop it.
A new technique called sci-Plex profiles gene expression in thousands of individual cells when a sample is perturbed, offering a global view of cellular responses. The results suggest that it could be scaled to thousands of samples to target diverse biochemical pathways.
The NeutroCure project focuses on harnessing the potential of reactive oxygen species (ROS) produced by neutrophils to treat inflammatory diseases. By developing safe ROS amplifiers, the consortium aims to selectively target pathogenic inflammation and cancer cells while minimizing damage to healthy tissues.
Researchers at Baylor College of Medicine discovered that immune checkpoint genes are more actively expressed in resistant tumors, which could be targeted with immunotherapy. This finding highlights the importance of personalized medicine and proper stratification of patients before treatment.
A City of Hope-led study found that tivozanib improved progression-free survival for patients with renal cell carcinoma who had tried two or more treatments, compared to the FDA-approved sorafenib. The study suggests that targeted therapy may be a better option for repeat kidney cancer patients.
Research presented at EuroEcho 2019 found that common heart drugs may reduce cardiotoxicity in cancer patients, particularly those with breast or haematological cancer. The study suggests these medications should be considered as part of routine care for this patient group.
Scientists at Scripps Research developed a method to rapidly discover compounds that restore anti-tumor activity in immune cells called T cells. The approach identified 19 compounds that can reawaken exhausted T cells, potentially leading to new combination-immunotherapy regimens against cancers and persistent infections.
A new Tel Aviv University study finds that consuming a starch-rich breakfast early in the morning and a small dinner may improve glycemic control among type 2 diabetics, reducing the need for insulin injections. The researchers' 3M-diet was shown to have significant benefits, including weight loss and improved sugar levels.
Research on exhausted CD8 T cells provides clues for refining cancer immunotherapy. A new study defines a transitional stage between stem-like and truly exhausted cells, which could be a target for therapy.
Researchers at the University of Cincinnati developed a new treatment for glioblastoma multiforme using coaxial electrospinning, which delivers a potent dose of medicine immediately or over time. The treatment improved survival rates in three separate animal trials and holds promise for other types of cancer.
Researchers at UT MD Anderson Cancer Center found TBK1 and its adaptor protein contribute to tumorigenesis when activated by growth factors. Targeting TBK1 inhibits tumor growth and promotes antitumor immunity in mouse models.
A clinical trial found that olaparib slowed or stopped tumour growth in men with advanced prostate cancer and BRCA mutations, with a median overall survival of 17.7 months. The study suggests that PARP inhibitors could become the first gene-targeted drug to be approved for prostate cancer.
Researchers at Karolinska Institutet found a new mechanism that renders the MYC gene overactive in cancer cells. The MYC gene is normally controlled by environmental cues and cell architecture, leading to uncontrolled growth.
Researchers on Australia's first space research mission to the International Space Station will investigate how microgravity affects aggressive cancers like ovarian, breast, and lung cancer. The mission may lead to new treatments that enhance existing therapies.
A researcher at Stephenson Cancer Center is investigating how tumor cells evade detection in lung cancer patients on immunotherapy medication. He believes that PD-L1-coated exosomes are neutralizing the antibody, allowing tumors to continue growing.
Researchers identified kynurenine and indoxyl sulfate as key culprits in generating clot formation in cancer patients via AHR signaling. These metabolites can be measured in the blood to predict risk of deep vein thrombosis, and their inhibition may lead to future drug development.
A phase III study shows that HLX02, a Chinese-made biosimilar of trastuzumab, has an overall response rate of 71% at week 24, comparable to the reference medication. The treatment is safe and effective, with similar rates of adverse events and no differences in safety profiles or immunogenicity.
Acalabrutinib, a second-generation Bruton tyrosine kinase inhibitor, has been approved by the FDA for first-line therapy in chronic lymphocytic leukemia (CLL) and small cell lymphoma (SML). The drug works by permanently binding to BTK, halting cancer cell growth signals.
Researchers found that extra DNA surrounding cancer-causing genes is crucial for maintaining their activation and supporting tumor growth. This discovery could explain why some cancer treatments are effective while others fail, and may lead to new therapeutic strategies.
Researchers at UTSA are developing new methods to synthesize organosulfur compounds, which are widely used in pharmaceuticals. The goal is to improve the accuracy and speed of these synthesis processes, leading to more effective medicines and potentially advancing functional materials.
The University of Illinois Chicago will help young breast cancer survivors navigate post-treatment care and survival with a $1.8 million CDC grant. The program aims to reduce disparities in survival and quality of life due to social factors among breast cancer survivors.
Researchers identified a panobinostat-marizomib combination that effectively kills childhood brain cancer cells and counters genetic mutations. The study uncovered a previously unrecognized vulnerability in cancer cells, which may lead to new strategies against the disease.
Researchers at Cold Spring Harbor Laboratory have developed a new therapy that extends the survival of mice with acute myeloid leukemia by blocking the Salt-Inducible Kinase 3 (SIK3) pathway. The treatment, YKL-05-099, is a first in demonstrating anti-cancer effects of SIK3 inhibition using pharmacological blockade.
Researchers identified molecular mechanisms underlying the lack of efficiency of nintedanib in squamous cell carcinoma and found smoking to be a key factor. The study suggests patients with adenocarcinoma may benefit from antifibrotic drugs like nintedanib combined with radiotherapy or immunotherapy.
The National Foundation for Cancer Research has named the winners of its Salisbury Award Competition, recognizing innovative cancer research projects. The winning project, led by Emily Han-Chung Hsiue and Jacqueline Douglass, targets cancer driver mutations with a novel antibody-based method.
The new guidelines call for better access to CDK4/6 inhibitors and anti-HER2 therapies for patients with advanced breast cancer. Experts also stress the need for adequate pain control, particularly in countries where opioids are scarce or misused.
Scientists at Sanford Burnham Prebys Medical Discovery Institute identified a combination of two anti-cancer compounds that shrank pancreatic tumors in mice, supporting the immediate evaluation of the drugs in a clinical trial. The study provides rationale for an immediate clinical trial evaluating the 2 therapies
Scientists at UCLA Jonsson Comprehensive Cancer Center developed a new high-throughput screening system that identifies selective inhibitors of metabolic pathways. The approach revealed multiple kinase inhibitors block nucleotide metabolism and its targets.
A new study finds that nearly half of 50- to 64-year-olds think they're likely to develop dementia, but only 5% have talked to a doctor about reducing their risk. Meanwhile, many use unproven tactics like supplements and brain games to stave off the disease.
The study found that T-DM1 resulted in a third of patients experiencing objective response and nearly 40% continuing treatment for at least six months. Patients with central nervous system metastases had shorter progression-free survival rates, highlighting the need for inclusion in randomized trials.
Researchers at Princess Margaret Cancer Centre have identified new protein targets for drug development against prostate cancer by analyzing noncoding DNA regions. These regions, previously thought to be 'junk' DNA, were found to harbor important regulatory elements that determine gene expression.
A novel mathematical framework has been developed to map out precisely how different perturbations of the interactome influence each other. The study reveals that the position of targets of a given drug on the interactome is not random but rather localized within drug modules.
A new biomarker, plectin, has been identified in cancer stem cells, which govern cancer survival and spread. Plectin's translocation onto the cell surface is linked to tumor invasion and metastasis, making it a potential target for drug development.
A study published in JAMA reports that cardiac resynchronization therapy can significantly improve heart function in cancer survivors with congestive heart failure. After six months, the patients experienced improved heart function, reduced symptoms, and enhanced quality of life. The therapy offers a possible solution for patients who ...
Biomedical engineers have combined ultrafast ultrasound imaging with ultrasonic tweezers to precisely track and target drug carriers within a phantom blood vessel. This new method could enable acoustic control and real-time tracking of drug release within the body, potentially improving targeted therapeutics.
Purdue University scientists have identified key changes in the blood-brain barrier that hinder effective drug delivery to brain tumors. The discovery aims to improve treatment plans and patient outcomes for those with brain metastases from breast, lung, and melanoma.
Researchers at the University of Michigan developed a small-molecule compound that harnesses the power of a natural cellular cleanup system to eliminate tumors. The degrader achieved nearly complete elimination of tumors in mouse models of leukemia and lymphoma, with lasting results.
Researchers at Texas Tech University Health Sciences Center have developed a novel drug combination using fenretinide and venetoclax to treat high-risk neuroblastoma. The study found that the combination of these two drugs showed significant activity against neuroblastoma cells, with multiple complete responses achieved in patients.
Scientists designed a novel approach to create stable and predictable antibody drug conjugates (ADCs) using computational docking molecular simulations. The new therapy, called MAGNET-ADC, can deliver cancer drugs specifically to tumor tissue with reduced toxicity.
Researchers identify a potential target for eliminating leukemia stem cells using vitamin K3, which stabilizes the DYRK2 enzyme. This approach could lead to treatment-free remissions and improved patient outcomes.
City of Hope researchers have created a modified CRISPR gene editing tool that improves the accuracy and efficiency of cutting out undesirable genetic information. The new design has shown promise in treating HIV and sickle cell disease by increasing desirable mutations and improving activity at specific target sites.
Dr. Yamamoto received the prestigious Karl Landsteiner Memorial Award and Lectureship for his work on blood group genes. He has contributed to a better understanding of glycosylation polymorphisms and cancer-specific glycosylation alterations.
Nami Therapeutics develops nanoparticles for targeted drug delivery, offering increased efficacy and reduced toxicity. The platform selectively targets ovarian cancer metastasis in the peritoneal cavity, improving survival rates.
A new USC study reveals that mint is the most popular flavor among U.S. teens who vape, contradicting previous studies that linked fruit flavors to teen vaping. The findings cast doubt on the effectiveness of JUUL's voluntary product removal and federal regulations aimed at reducing youth vaping.
Researchers identified four distinct immune-based subtypes of kidney cancer, which could help predict patient survival and response to treatment. The study also found that certain tumor microenvironment signatures were associated with better or worse overall survival.
The UCLA prostate cancer program has been awarded an $8.7 million SPORE grant to develop new approaches for improving diagnosis, prognosis, and treatment of prostate cancer. The grant will fund three translational research projects to find better ways to treat men with advanced stages of the disease.
A new study finds that acute kidney injury affects 17% of patients taking immunotherapy medications for cancer, while proton pump inhibitors increase the risk of sustained AKI. Nephrologists and oncologists must recognize these factors to diagnose and treat patients effectively.
Researchers at Rice University and MD Anderson Cancer Center have discovered a combination of drugs that target mitochondria can selectively kill leukemia cells while leaving healthy blood cells unaffected. This breakthrough could lead to more effective personalized treatment for patients with leukemia.
A modified Mycobacterium bovis Bacillus Calmette et Guérin (BCG) vaccine, dubbed dBCG, has been shown to be safer and more effective than traditional BCG therapy for bladder cancer. The new approach involves injecting dBCG directly into bladder cancer tumors to reduce recurrence and progression of the disease.
Gabapentinoid prescriptions for adults with cancer grew from 3.3% to 8.3% between 2005 and 2015, with total prescriptions increasing from 1.2 million to 3.5 million. Further study is needed to understand the effectiveness and risks of gabapentinoids in treating cancer pain.